Detalles de la búsqueda
1.
Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom.
Br J Cancer
; 2024 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38658782
2.
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study.
Breast Cancer Res Treat
; 199(1): 35-46, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36859649
3.
Do animal models of brain tumors replicate human peritumoral edema? a systematic literature search.
J Neurooncol
; 161(3): 451-467, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36757526
4.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Lancet Oncol
; 23(7): 851-864, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35671774
5.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Lancet
; 398(10318): 2258-2276, 2021 12 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34863358
6.
Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework.
Br J Cancer
; 125(2): 155-163, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33850304
7.
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Br J Cancer
; 124(8): 1379-1387, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33623076
8.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Lancet Oncol
; 21(3): 345-357, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32035020
9.
Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.
Br J Cancer
; 123(5): 694-697, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32572174
10.
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.
Br J Cancer
; 122(9): 1324-1332, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32161368
11.
Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre.
BMC Cancer
; 20(1): 53, 2020 Jan 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31964373
12.
Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis.
Breast J
; 26(7): 1347-1351, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31782589
13.
A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.
Br J Cancer
; 120(6): 579-586, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30783204
14.
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.
Future Oncol
; 15(19): 2211-2225, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31074641
15.
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Breast Cancer Res Treat
; 165(2): 329-341, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28612225
16.
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 16(15): 1556-1568, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26482278
17.
Breast cancer-related lymphoedema and venepuncture: a review and evidence-based recommendations.
Breast Cancer Res Treat
; 154(3): 455-61, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26589315
18.
Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.
Breast Cancer Res Treat
; 154(3): 509-20, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26567010
19.
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Lancet Oncol
; 15(13): 1481-1492, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25456367
20.
Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency.
J Hepatol
; 61(5): 1135-42, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24993530